Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Artelo Biosciences Inc (ARTL)

Artelo Biosciences Inc (ARTL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,647
  • Shares Outstanding, K 3,228
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,290 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.74
  • Number of Estimates 1
  • High Estimate -0.74
  • Low Estimate -0.74
  • Prior Year -0.99
  • Growth Rate Est. (year over year) +25.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0200 +15.69%
on 11/15/24
1.3200 -10.61%
on 11/18/24
-0.0400 (-3.28%)
since 10/22/24
3-Month
1.0000 +18.00%
on 09/10/24
1.3200 -10.61%
on 11/18/24
-0.0700 (-5.60%)
since 08/22/24
52-Week
1.0000 +18.00%
on 09/10/24
1.7500 -32.57%
on 02/14/24
-0.0362 (-2.98%)
since 11/22/23

Most Recent Stories

More News
Artelo Biosciences to Present Innovations in Cannabinoid-Derived Drug Development at Boston Summit

Artelo Biosciences will present innovative drug development data at the Cannabinoid-Derived Drug Development Summit in Boston.Quiver AI SummaryArtelo Biosciences, Inc. announced that Professor Saoirse...

ARTL : 1.1534 (+2.07%)
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit 

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program

ARTL : 1.1534 (+2.07%)
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy ...

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss

Initiates Fourth Cohort at a 650-Microgram Dose with Data Expected in Q4 2022 ...

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...

ARTL : 1.1534 (+2.07%)
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th...

ARTL : 1.1534 (+2.07%)

Business Summary

Artelo Biosciences Inc. is a biopharmaceutical company. It is engaged in development and commercialization of proprietary therapeutics targeting the endocannabinoid system. The company's product pipeline consists of ART27.13, ART12.11 and ART26.12 which are in clinical stage. Artelo Biosciences Inc....

See More

Key Turning Points

3rd Resistance Point 1.1970
2nd Resistance Point 1.1836
1st Resistance Point 1.1568
Last Price 1.1534
1st Support Level 1.1166
2nd Support Level 1.1032
3rd Support Level 1.0764

See More

52-Week High 1.7500
Fibonacci 61.8% 1.4635
Fibonacci 50% 1.3750
Fibonacci 38.2% 1.2865
Last Price 1.1534
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar